address1,address2,city,zip,country,phone,website,industry,industryKey,industryDisp,sector,sectorKey,sectorDisp,longBusinessSummary,companyOfficers,compensationAsOfEpochDate,executiveTeam,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,dividendRate,dividendYield,exDividendDate,payoutRatio,beta,trailingPE,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,tradeable,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,earningsQuarterlyGrowth,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,lastDividendValue,lastDividendDate,quoteType,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,earningsGrowth,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,symbol,language,region,typeDisp,quoteSourceName,triggerable,customPriceAlertConfidence,exchange,messageBoardId,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,market,esgPopulated,shortName,longName,corporateActions,regularMarketTime,regularMarketChange,regularMarketDayRange,fullExchangeName,averageDailyVolume3Month,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekChangePercent,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,earningsCallTimestampStart,earningsCallTimestampEnd,isEarningsDateEstimate,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,sourceInterval,exchangeDataDelayedBy,averageAnalystRating,cryptoTradeable,regularMarketChangePercent,regularMarketPrice,marketState,hasPrePostMarketData,firstTradeDateMilliseconds,trailingPegRatio
Velankani Technology Park,"Block II, First Floor Electronic City Phase I",Bengaluru,560100,India,91 80 6891 9191,https://www.syngeneintl.com,Diagnostics & Research,diagnostics-research,Diagnostics & Research,Healthcare,healthcare,Healthcare,"Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.","[{'maxAge': 1, 'name': 'Mr. Peter James Jonathan Bains', 'age': 67, 'title': 'CEO & MD', 'yearBorn': 1957, 'fiscalYear': 2017, 'totalPay': 400000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Deepak  Jain', 'title': 'Chief Financial Officer', 'fiscalYear': 2017, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jayashree  Aiyar Ph.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2017, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Krishnan  G', 'title': 'Head of Investor Relations', 'fiscalYear': 2017, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Sandeep  Nair', 'title': 'Head of Corporate Communications', 'fiscalYear': 2017, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Andrew  Webster', 'title': 'Chief Human Resources Officer', 'fiscalYear': 2017, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Dhananjay  Patankar', 'title': 'Head of Pharmaceutical & Biopharmaceutical Development', 'fiscalYear': 2017, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Purushottam Shashikant Singnurkar', 'title': 'Head of Formulations Development', 'fiscalYear': 2017, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ajit  Manocha', 'title': 'Head of IT', 'fiscalYear': 2017, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Chetan Prakash Tamhankar', 'title': 'Head of Clinical Development & Stability Studies', 'fiscalYear': 2017, 'exercisedValue': 0, 'unexercisedValue': 0}]",1514678400,[],86400,2,627.25,625.0,624.35,636.0,627.25,625.0,624.35,636.0,1.25,0.2,1750896000,0.1012,0.153,51.067963,37.45994,1166094,1166094,1304342,775077,775077,0.0,0.0,0,0,253595959296,599.55,960.6,6.9623313,654.806,775.723,1.25,0.001992826,INR,False,243941998592,0.13623,177591974,401768000,0.53177,0.33812,412240000,117.59,5.3678036,1743379200,1774915200,1743379200,-0.028,4961999872,12.36,16.85,2:1,1560211200,6.697,23.373,-0.12020481,0.094471335,1.25,1750982400,EQUITY,631.2,825.0,570.0,712.2222,700.0,2.55556,hold,9,13975000064,34.766,10437000192,5778999808,1.395,1.638,36423999488,12.226,90.656,0.059,0.11046,26998999040,2142499968,11676000256,-0.028,0.11,0.74124,0.28654,0.23782,INR,SYNGENE.NS,en-US,US,Equity,Delayed Quote,True,HIGH,NSI,finmb_28623664,Asia/Kolkata,IST,19800000,in_market,False,SYNGENE INTERNATIONAL LTD,Syngene International Limited,"[{'header': 'Dividend', 'message': 'SYNGENE.NS announced a cash dividend of 1.25 with an ex-date of Jun. 27, 2025', 'meta': {'eventType': 'DIVIDEND', 'dateEpochMs': 1750962600000, 'amount': '1.25'}}]",1750413600,3.9500122,624.35 - 636.0,NSE,1304342,31.650024,0.052789632,599.55 - 960.6,-329.39996,-0.34291065,-12.020481,1745405940,1753181940,1753531200,1745472600,1745472600,True,12.36,16.85,10.8913,57.954514,-23.606018,-0.036050398,-144.52301,-0.18630749,15,15,2.6 - Hold,False,0.6297349,631.2,POSTPOST,False,1439264700000,
